Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vactosertib by MedPacto for Osteosarcoma: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs...
Vactosertib by MedPacto for Metastatic Colorectal Cancer: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Vactosertib by MedPacto for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
Vactosertib by MedPacto for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to GlobalData,...
Vactosertib by MedPacto for Non-Hodgkin Lymphoma: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...
Vactosertib by MedPacto for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
Vactosertib by MedPacto for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...
Vactosertib by MedPacto for Acute Lymphoblastic Lymphoma: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Acute Lymphoblastic Lymphoma. According to GlobalData, Phase...